Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Absci Corp

Ticker
ABSI
Sector
Industry
Report date
November 15, 2026
Valye AI Score

91

Very high visibility
Recent developments
Recent developments summary

Recent developments include Absci's Q3 2026 financial results and clinical pipeline updates, multiple earnings call transcripts, and reports of a Q3 loss with revenue challenges. The company reported encouraging Phase 1 safety data for ABS-201 and maintains strong liquidity.

Recent developments:
  • Absci reported third quarter 2026 financial results and clinical pipeline updates highlighting ongoing development activities and financial condition [N1].
  • The Q3 2026 earnings call transcript and highlights detailed operational progress and financial results, including a net loss and revenue from partnered drug creation activities [N2][N3].
  • Absci reported a Q3 loss and missed revenue expectations, reflecting challenges in commercializing its drug creation platform and internally developed programs [N4].
  • The company maintains strong liquidity with $173.7 million in cash, cash equivalents, and marketable securities as of September 30, 2026, supporting operations for at least the next 12 months [S2].
  • Encouraging Phase 1 safety data was reported for ABS-201, an internally developed program, indicating progress in clinical development [N1].
Overview

Absci Corp operates as a clinical-stage biopharmaceutical company leveraging an Integrated Drug Creation platform that combines AI and biopharmaceutical research to discover and develop biologic drug candidates. The company focuses on advancing internally developed programs through nonclinical and clinical development while also engaging in drug creation collaborations and co-development partnerships with third parties. Revenue to date has been generated primarily from drug creation activities under partnered programs, with no commercial product sales yet. Absci faces the challenge of transitioning from a research-focused entity to one capable of supporting commercial activities. The company has incurred significant losses since inception and maintains liquidity through cash, cash equivalents, and marketable securities. Its future growth depends on advancing its internally developed programs and the success of partners in developing and commercializing therapies based on its platform. Risks include clinical development uncertainties, regulatory approval challenges, competition, and the need for additional capital.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Absci Corp is a clinical-stage biopharmaceutical company focused on drug discovery using its Integrated Drug Creation platform. The company has not generated revenue from commercial product sales and relies on partnered drug creation activities for revenue. It has incurred significant losses and maintains strong liquidity with $173.7 million in cash and marketable securities as of September 30, 2026. Risks include the early stage of its business model, clinical development uncertainties, regulatory challenges, and the need for additional capital to fund operations and growth [S1][S2][N1][N4].

Scenarios for ABSI

Bull case model:

Absci's Integrated Drug Creation platform leverages AI to potentially accelerate biologic drug discovery and development, offering a differentiated approach in the biopharmaceutical industry. The company has initiated multiple partnered programs and is advancing internally developed clinical programs, including ABS-201 with encouraging Phase 1 safety data. Strong liquidity supports ongoing operations and development activities. Successful advancement of clinical programs and establishment of long-term license agreements with partners could enhance revenue streams and validate the platform's value. Expansion of AI capabilities and platform applications into new research areas may provide additional growth avenues.

Bear case model:

Absci remains in early clinical and nonclinical development stages with no commercial product sales, resulting in significant accumulated losses and ongoing operating expenses. The drug creation collaboration business model is nascent, with no partners having entered into clinical or commercial licenses to date. Clinical development and regulatory approval risks are substantial, with inherent uncertainties in biologic drug development. The company depends on raising additional capital to fund operations and development, which may dilute shareholders or impose restrictive covenants. Failure to secure partnerships, achieve regulatory milestones, or commercialize products could materially harm business prospects and financial condition.

Moat:

Absci's moat is centered on its Integrated Drug Creation platform, which integrates AI capabilities with biopharmaceutical research to accelerate drug discovery and development. This platform aims to create biologic drug candidates more efficiently and to support partnered drug creation programs. The company's early-stage collaborations and proprietary technology provide potential competitive advantages in the biologic drug discovery space. However, the moat is contingent on successful clinical development, regulatory approvals, and the ability to establish long-term partnerships that generate milestone and royalty revenues. The platform's expansion into additional areas of biopharmaceutical research and development could further strengthen its competitive position if successfully executed.

Risks overview
Risks summary
The biggest risks for Absci include the early stage of its clinical programs and business model, significant clinical and regulatory uncertainties, dependence on partnerships for revenue, and the need for additional capital to sustain operations and development.
Risks details:

• Early Stage and Operating History: Absci's short operating history and early-stage clinical programs make it difficult to assess future viability and success. Transitioning from research to commercial operations presents challenges.
• Clinical Development and Regulatory Risks: The company faces inherent uncertainties in biologic drug development, including potential failure to achieve regulatory approvals or commercial viability for product candidates.
• Dependence on Partnerships and Licensing: Revenue depends on successful drug creation collaborations and entering into long-term license agreements with partners, none of which have yet resulted in clinical or commercial licenses.
• Financial Condition and Capital Needs: Absci has incurred significant losses and requires additional capital to fund operations and development. Financing activities may dilute stockholders or impose restrictive covenants.
• Market Acceptance and Competition: Even if approved, product candidates may not achieve broad market acceptance. Competition and technological developments may adversely affect the company's prospects.

FINAL FORECAST FOR ABSI

Final take one line
Absci Corp is a clinical-stage biopharmaceutical company with a high-visibility drug creation platform facing typical early-stage development and financial risks.
Final take 12 to 24 month view

Business trends: Advancement of internally developed clinical programs and expansion of AI-driven drug creation collaborations.
Execution milestones: Progress in clinical trials including Phase 1 safety data, securing long-term licensing agreements with partners, and maintaining liquidity.
Key risks: Clinical and regulatory uncertainties, dependence on partnerships for revenue, and the need for additional capital to sustain operations.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

91
LLM visibility overview
LLM Visibility known facts
  • Absci Corp is a clinical-stage biopharmaceutical company focused on drug discovery and development using its Integrated Drug Creation platform.
  • The company has not yet generated revenue from commercial product sales and all internally developed programs are in nonclinical or early clinical development stages.
  • Revenue to date has been primarily generated from drug creation activities conducted through partnered programs, with no partners having entered into licenses for clinical or commercial use of intellectual property as of November 12, 2026.
  • The business model depends on successfully completing drug creation phases and entering into long-term license arrangements with partners to receive milestone payments and royalties.
  • Absci has incurred significant losses since inception, including a net loss of $33.3 million for the nine months ended September 30, 2026, and an accumulated deficit of $720.9 million as of that date.
  • As of September 30, 2026, Absci had $173.7 million in cash, cash equivalents, and marketable securities, with a current ratio of 9.64 and a cash ratio of 9.21, indicating strong liquidity.
  • The company expects its current cash and anticipated cash flows to be sufficient to meet working capital and capital expenditure needs for at least the next 12 months.
  • Risks include the uncertainty inherent in biologic drug development, the early stage of the company's drug creation collaboration business model, and the need for additional capital to fund operations and clinical development.
  • The company faces risks related to clinical development, regulatory approval, manufacturing, commercialization, and competition, both for its internally developed programs and partnered programs.
  • Positive early-stage clinical or nonclinical results may not predict later-stage success, and there is no assurance that any product candidates will receive regulatory approval or achieve commercial viability.
  • Absci's future growth depends on advancing internally developed programs and the success of partners in developing and commercializing therapies based on its platform.
  • The company may raise additional capital through equity or debt financing, which could dilute stockholders or impose restrictive covenants.
  • Absci's recent financial disclosures include a Q3 2026 report filed on November 12, 2026, and an annual report filed on March 24, 2026, detailing risk factors and financial condition.
  • Recent news includes multiple earnings call transcripts and financial results reports for Q3 2026, highlighting a Q3 loss and revenue challenges.
  • The company announced clinical pipeline updates and reported encouraging Phase 1 safety data for ABS-201, a program in development.
  • Absci's drug creation platform leverages AI capabilities and aims to expand into additional areas of biopharmaceutical research and development.
  • The company is transitioning from a research-focused entity to one capable of supporting commercial activities, which presents operational challenges.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
  • N2
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-24 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Absci Corporation Reports Third Quarter 2026 Financial Results and Clinical Pipeline Updates | https://www.nasdaq.com/articles/absci-corporation-reports-third-quarter-2026-financial-results-and-clinical-pipeline
  • N2 | 2026-11-12 | www.nasdaq.com | Absci (ABSI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/absci-absi-q3-2026-earnings-call-transcript
  • N3 | 2026-11-12 | www.nasdaq.com | Absci Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/absci-q3-earnings-call-highlights
  • N4 | 2026-11-12 | www.nasdaq.com | Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/absci-corporation-absi-reports-q3-loss-misses-revenue-estimates
  • N5 | 2026-11-10 | www.nasdaq.com | Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/scholar-rock-holding-corporation-srrk-reports-q3-loss-beats-revenue-estimates
  • N6 | 2026-11-05 | www.nasdaq.com | Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/verastem-vstm-reports-q3-loss-misses-revenue-estimates
  • N7 | 2026-08-19 | www.nasdaq.com | Absci (ABSI) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/absci-absi-q2-2026-earnings-call-transcript
  • N8 | 2026-08-18 | www.nasdaq.com | The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci | https://www.nasdaq.com/articles/zacks-analyst-blog-highlights-recursion-pharmaceuticals-schrodinger-relay-therapeutics-and
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine